![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » REIMBURSEMENT LEVELS RISING IN POLAND
REIMBURSEMENT LEVELS RISING IN POLAND
Poland's National Health Fund (NFZ) estimates that drug reimbursement spending increased by PLN215mn (US$67.15mn) in the first half of 2005, an 8.2% increase on levels reported in 2004. Total reimbursement was PLN8.9bn (US$2.79bn) in 2004, with consumers covering 31% of this cost, and the number of packets sold is estimated at 362mn.
Healthcare expenditure has been rising in Poland, as the country attempts to implement European Union (EU) legislation. Furthermore, 45% of reimbursement spending was allocated to chronic problems, including diabetes and central nervous system disorders. Notably, locally manufactured generics account for the overwhelming majority of Poland's reimbursement list.
Nevertheless, Poland has one of the lowest levels of healthcare spending in the EU. The country also has a high patient co-payment ratio -- which can be 33.7% on average, but up to 55% for some prescription drugs. The NFZ also admits that there is no epidemiological explanation for wide discrepancies between spending in Poland's regions.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct